Sanara MedTechSMTI +1.38%72 FCF Margin % is -9.03% as of Mar. 2026. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.52 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Sanara MedTech ranks better than 58.04% on this metric.
The historical rank and industry rank for Sanara MedTech's FCF Margin % or its related term are showing as below:
SMTI'
s FCF Margin % Range Over the Past 10 Years
Min: -36.43 Med: -4.49 Max: 7.37
Current: 3.12
During the past 13 years, the highest FCF Margin % of Sanara MedTech was 7.37%. The lowest was -36.43%. And the median was -4.49%.
SMTI's FCF Margin % is ranked better than 58.04% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs SMTI: 3.12
Sanara MedTech FCF Margin % Related Terms
Sanara MedTech FCF Margin % Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Sanara MedTech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanara MedTech (SMTI) has a FCF Margin % of -9.03% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sanara MedTech and its competitors. According to the industry distribution chart, Sanara MedTech ranks #342 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 42%.
Is Sanara MedTech's FCF Margin % too high?
Sanara MedTech's current FCF Margin % is -9.03%. Based on the distribution chart, Sanara MedTech ranks #342 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's FCF Margin % compare to PDEX and UTMD?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #342 out of 815 companies for FCF Margin %. This puts Sanara MedTech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sanara MedTech and its competitors. Sanara MedTech's current FCF Margin % is -9.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.52, compared to a current price of $23.19 — trading 49.1% below its estimated fair value. The current FCF Margin % is -9.03%. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current FCF Margin % is -9.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $23.19 is trading 49.1% below its estimated GF Value™ of $45.52.
GuruFocus considers Sanara MedTech to be Possible Value Trap.
Key valuation signals for SMTI:
FCF Margin %: -9.03%
GF Value™: $45.52 vs. price of $23.19 (49.1% below fair value)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score
Get the complete analysis for SMTI
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
